BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
64.26
+0.81 (1.28%)
Nov 22, 2024, 4:00 PM EST - Market closed
BioMarin Pharmaceutical Employees
BioMarin Pharmaceutical had 3,401 employees as of December 31, 2023. The number of employees increased by 319 or 10.35% compared to the previous year.
Employees
3,401
Change (1Y)
319
Growth (1Y)
10.35%
Revenue / Employee
$809,412
Profits / Employee
$94,764
Market Cap
12.25B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 3,401 | 319 | 10.35% |
Dec 31, 2022 | 3,082 | 37 | 1.22% |
Dec 31, 2021 | 3,045 | -14 | -0.46% |
Dec 31, 2020 | 3,059 | 58 | 1.93% |
Dec 31, 2019 | 3,001 | 152 | 5.34% |
Dec 31, 2018 | 2,849 | 268 | 10.38% |
Dec 31, 2017 | 2,581 | 288 | 12.56% |
Dec 31, 2016 | 2,293 | 135 | 6.26% |
Dec 31, 2015 | 2,158 | 477 | 28.38% |
Dec 31, 2014 | 1,681 | 340 | 25.35% |
Dec 31, 2013 | 1,341 | 252 | 23.14% |
Dec 31, 2012 | 1,089 | 87 | 8.68% |
Dec 31, 2011 | 1,002 | 131 | 15.04% |
Dec 31, 2010 | 871 | 151 | 20.97% |
Dec 31, 2009 | 720 | 71 | 10.94% |
Dec 31, 2008 | 649 | 124 | 23.62% |
Dec 31, 2007 | 525 | 115 | 28.05% |
Dec 31, 2006 | 410 | 96 | 30.57% |
Dec 31, 2005 | 314 | -45 | -12.53% |
Dec 31, 2004 | 359 | 87 | 31.99% |
Dec 31, 2003 | 272 | 53 | 24.20% |
Dec 31, 2002 | 219 | 3 | 1.39% |
Dec 31, 2001 | 216 | 42 | 24.14% |
Dec 31, 2000 | 174 | 25 | 16.78% |
Dec 31, 1999 | 149 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Fresenius Medical Care AG | 119,845 |
Universal Health Services | 96,700 |
Dr. Reddy's Laboratories | 27,048 |
Solventum | 20,098 |
AptarGroup | 13,800 |
Globus Medical | 5,000 |
Bio-Techne | 3,050 |
Genmab | 2,204 |
BMRN News
- 2 days ago - Biomarin: Challanges Mount, But Sale Rumours Make For A Risky "Buy" Call - Seeking Alpha
- 7 days ago - BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024 - PRNewsWire
- 17 days ago - BioMarin to Participate in Three Upcoming Investor Conferences - PRNewsWire
- 24 days ago - BioMarin Pharmaceutical Inc. (BMRN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 25 days ago - BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook - PRNewsWire
- 5 weeks ago - BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET - PRNewsWire
- 6 weeks ago - 3 Oversold Stocks with Big RSI Rebound Potential - Benzinga
- 2 months ago - BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish - Benzinga